Life Technologies forms GIBCO Cell Therapy Systems

Life Technologies Corporation (NASDAQ:LIFE) today announced the formation of GIBCO^® Cell Therapy Systems (CTS™), which will offer the life science industry's widest array of products to support cell therapy applications, including regenerative medicine. Specifically designed to help cell therapy practitioners accelerate the transition from research to clinical applications, the product portfolio will include a broad and deep offering of Invitrogen devices and reagents.

“We've leveraged our expertise, as well as our broad and deep product portfolio to create workflow solutions for cell therapy that will help investigators move their research applications into the clinic more quickly and efficiently, while enhancing patient safety”

Cell therapy practitioners today spend a lot of time and money assembling and qualifying the tools and reagents required to move a cell therapy concept from a laboratory environment to the clinic in a regulatory compliant and highly supported process. Cell-based therapies have hundreds of potential applications addressing unmet medical needs, including neurological disorders, heart disease, cancer, auto-immune disease, infectious disease, as well as tissue repair where conventional pharmaceuticals may be ineffective. With the regenerative medicine field experiencing explosive growth, from $1.6 billion to $15 - $20 billion over the next 15 years₁, Life Technologies is building a portfolio of bundled tools and reagents to address this challenge and help researchers accelerate the process of moving their potential solutions into a clinical environment.

"Documentation is a critical aspect of bringing novel cell therapies to the clinic," said Dr. Larry Couture, Senior Vice President and Founding Director of the Center for Applied Technology Development; Director for the Center for Biomedicine and Genetics at the City of Hope in Duarte, California. "Having proper quality systems in place, appropriate documentation, and a stable supply chain is critical, both in the pre-clinical development phase, as well as further down the road during clinical trials."

The CTS product portfolio will provide media, reagents, enzymes, buffers, growth factors, selection-beads and magnets, and other components of integrated workflow solutions. The high-quality materials will come with easily accessible documentation, such as certificates of analysis and certificates of origin. Moreover, the products will be backed up with the highest level of technical, regulatory and web-based support.

"We've leveraged our expertise, as well as our broad and deep product portfolio to create workflow solutions for cell therapy that will help investigators move their research applications into the clinic more quickly and efficiently, while enhancing patient safety," said Paul Pickering, General Manager of Cell Therapy Systems at Life Technologies. "We anticipate that this offering will enable us to form collaborations with key industry leaders, and help reduce their burden in qualifying tools and reagents as they prepare to move their cell therapy concepts into the clinic, which will ultimately help improve the human condition and address unmet medical need."

SOURCE Life Technologies Corporation